🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Integrating Artificial Intelligence Into Lung Cancer Screening.

RecruitingNAAges 18 Years - 80 YearsAllCentre Hospitalier Universitaire de Nice
NCT05704920 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Lung cancer (LC) screening using low-dose chest CT (LDCT) has already proven its efficacy. The mortality reduction associated with LC screening is around 20%, much higher than the reduction in mortality associated with screening for breast, colon or prostate cancers. Implementing lung cancer screening on a large scale faces two main obstacles: 1. The lack of thoracic radiologists and LDCT necessary for the eligible population (between 1.6 and 2.2 million people in France); 2. The high frequency of false positive screenings: in the NLST trial, more than 20% of the subjects screened were found to have at least one nodule of an indeterminate lung nodule (ILN) whereas less than 3% of ILNs are actually LC. The gold standard for determining on the benign or malignant nature of a nodule is definitive histology. Otherwise, the evolution of the nodule on serial thoracic imaging is a good alte

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Age between 50 and 80 years old * active smoker or ex-smoker who quit smoking less than 15 years ago * smoking history of at least 20 pack-years * signature of the informed consent * affiliation to French social security Exclusion Criteria: * clinical signs suggestive of cancer * recent chest scan (\<1 year) for another cause * radiological abnormality requiring follow-up or additional investigations * health problem significantly limiting life expectancy from the clinician's point of view * health problem limiting ability or willingness to undergo lung surgery * Patients with active neoplasia, except basal cell carcinoma of the skin. * vulnerable people: adults under guardianship, adults under curatorship medical and/or psychiatric problems of sufficient severity to limit full adherence to the study or expose patients to excessive risk
💊

What it tests

  • IA
  • Not IA
📍

Where

1 site
CHU de Nice - Hôpital de Pasteur
Nice, France
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy